February 19, 2018 3:47 PM ET

Healthcare Equipment and Supplies

Company Overview of Gardia Medical Ltd.

Company Overview

Gardia Medical Ltd. develops and sells catheter-based delivery systems that integrate with the workflow of stenting and cardiovascular intervention procedures. It offers embolic protection device, a wire-independent distal filtration system that reduces the incidence of embolic complications during stenting procedures, such as carotid and SVG angioplasty. The company’s deliver, lock, and deploy technology enables in-situ locking of cardiovascular devices, as well as addresses various applications in the field of interventional cardiology, including renal, PAD, and coronary stenting. It serves cardiologists in the United States. Gardia Medical Ltd. was founded in 2006 and is based in Caesarea...

13 Granit Street

North Industrial Park

Caesarea,  38900


Founded in 2006


972 4 627 7994


972 4 627 7995

Key Executives for Gardia Medical Ltd.

Chief Executive Officer
Age: 56
Founder and Chief Medical Consultant
Founder and Chief Technology Officer
General Manager
Vice President of Regulatory and Clinical Affairs
Compensation as of Fiscal Year 2017.

Gardia Medical Ltd. Key Developments

Gardia Medical Demonstrates Enhanced Safety in Lower Extremity Interventions

Gardia Medical announced that according to the independent Clinical Events Committee (CEC), Gardia successfully met the primary end-point in its WISE-LE study. The WISE-LE study's objective is to demonstrate the safety and performance of the WIRION EPS in subjects undergoing LE atherectomy for the treatment of Peripheral Arterial Disease. The Primary Investigator of the Study is Dr. Bill Gray from Lankenau Heart Institute in Philadelphia. According to the IDE approved study protocol, the primary end-point for the WISE-LE performance-goal study is freedom from MAEs to 30 days post procedure. The performance goal was based on Covidien's DEFINITIVE LE and DEFINITIVE Ca++ trials. Currently, Covidien's SpiderFX in the only embolic protection system cleared for the LE indication in the US. The study protocol specified enrollment of 153 patients with the primary end point successfully met if 18 (12.0%) or less MAEs occurred according to CEC adjudication. An interim analysis was performed at 100 patients and the study was stopped for success at interim given the single MAE versus the 9 (9%) allowed for success. Gardia is expecting to receive an Atherectomy Independent Labeling that will cover use with all atherectomy devices. The SpiderFX, the only FDA cleared EPD for the LE indication is limited for use with a specific atherectomy device.

Similar Private Companies By Industry

Company Name Region
2P2D Solutions Ltd. Middle East/Africa
4C Diagnostics Ltd. Middle East/Africa
A.B. Dental Devices, Limited Middle East/Africa
Accurate Medical Therapeutics Ltd. Middle East/Africa
ActiVein Inc. Middle East/Africa

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Gardia Medical Ltd., please visit www.gardiamedical.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.